CEACAM5 expression
CEACAM5 is the cell-surface form of the tumour marker CEA, high on many lung and bowel cancers. Tusamitamab ravtansine was tested in CEACAM5-high lung cancer but failed its phase 3 and no approval exists.
Overview
The CARMEN-LC03 trial (NCT04154956) selected non-squamous NSCLC with CEACAM5 expression at 2+ intensity in 50 percent or more of tumour cells by IHC; it did not meet its endpoints and development stopped in 2023. Newer CEACAM5 ADCs and bispecifics are in early trials with similar IHC gates. No label names CEACAM5.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · The classic 'CEA' tumour marker measured in blood, also present on the cell surface where ADCs can reach it.
CEACAM5 staining is not a routine test and no approved drug depends on it; the one late-stage antibody-drug conjugate aimed at it did not succeed. Trials of newer CEACAM5 drugs may use the stain to select patients.
Written only from the label or guideline text cited on this page. Not medical advice; your own report and the reading your team gives it come first.
The label names the antigen in the drug's description but does not require it to be measured before treatment; no approval threshold exists for this readout.
“CARMEN-LC03: tusamitamab ravtansine versus docetaxel in CEACAM5-positive non-squamous NSCLC”
ClinicalTrials.gov NCT04154956 (CARMEN-LC03)No approval uses this readout as a threshold. It is defined by CARMEN-LC03 (NCT04154956): CEACAM5 IHC 2+ in >= 50% of tumour cells.
Matched on the name and aliases of the readout in the title, setting and summary of each trial; a match is a mention, not proof the readout was an entry criterion.
- NCT07462650Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer
- NCT07641036Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer
- NCT07589517Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer
- NCT07387081Phase II Study of LM-24C5
- NCT04154956SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients
- NCT06710132Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
- NCT04524689Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC
- NCT04659603Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors
Similar pages
not linked directly; found by shared links- BiomarkerNectin-4 expression
Shares TROP2 expression and the tags biomarker, surface-antigen, no-threshold.
- BiomarkerHER3 expression
Shares Non-small-cell lung cancer and the tags biomarker, surface-antigen, no-threshold.
- BiomarkerB7-H3 (CD276) expression
Shares the tags biomarker, surface-antigen, no-threshold.
- BiomarkerBCMA expression
Shares the tags biomarker, surface-antigen, no-threshold.
- BiomarkerCD38 expression
Shares the tags biomarker, surface-antigen, no-threshold.
- BiomarkerDLL3 expression
Shares the tags biomarker, surface-antigen, no-threshold.
- BiomarkerFcRH5 expression
Shares the tags biomarker, surface-antigen, no-threshold.
- BiomarkerGPRC5D expression
Shares the tags biomarker, surface-antigen, no-threshold.